On August 18, Zhifei Bio(300122) issued an announcement that the adsorbed acellular diphtheria, tetanus and pertussis (component) combined vaccine (for adults and adolescents) developed by the company's wholly-owned subsidiary Zhifei Green Bamboo recently obtained the National Medical Products Administration's drug clinical trial application acceptance notice.

This vaccine is a combination vaccine targeting pertussis (whooping cough), diphtheria, and tetanus, and is suitable for healthy individuals aged seven years and above. Currently, no component DTP vaccine has been approved for use in adolescents and adults in China, and the market prospects are promising.

The announcement noted that the acceptance of the clinical trial application for the adolescent and adult diphtheria, pertussis, and tetanus vaccine is the result of the company's technological innovation and scientific research. If the project progresses smoothly, it will further strengthen the company's market competitiveness, enrich its product portfolio, and enhance profitability. The company reminds investors that drug development is complex and high-risk, and that the progress and results of clinical trials are uncertain. Near-term performance will not be significantly impacted by this.

By mid-2025, Zhifei Bio achieved revenue of 4.919 billion yuan and a net profit attributable to shareholders of the parent company of -597 million yuan.

https://finance.eastmoney.com/a/202508183487093539.html